June 29, 2020
Seattle Genetics’s testing tisotumab vedotin in recurrent or metastatic cervical cancer (updated)
Seattle Genetics’ results from the phase 2 of trial testing tisotumab vedotin to treat patients with relapsed or progressed metastatic cervical cancer, showed clinically meaningful and durable objective responses with a manageable safety profile.